NCT05055947View on ClinicalTrials.gov

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

September 14, 2021

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

First line EC/EP+Atezolizumab

Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT05055947 - Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter